Page last updated: 2024-11-12

mart-1 antigen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9897305
CHEMBL ID261936
MeSH IDM0545549

Synonyms (14)

Synonym
NCGC00167162-01
CHEMBL261936 ,
bdbm50409412
mart-1 (27-35) (human)
mart-1 antigen
874310-50-6
mart1 antigen
dna (human gene mart1 antigen mart-1 cdna plus flanks)
unii-izr7iv8369
mart-1(27-35) peptide antigen
IZR7IV8369 ,
melan - a/mart - 1 (27 - 35)
HY-106187
CS-0025153

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our adjuvant regimen combining PF-3512676 and granulocyte macrophage-colony stimulating factor was safe and is worthy of further testing with these or alternative peptides, potentially in combination with antibodies that target immunoregulatory checkpoints."( Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.
Gooding, WE; Kirkwood, JM; Leng, S; Lin, Y; Moschos, SJ; Sander, C; Tarhini, AA; Yin, Y, 2012
)
0.38
"Here, we describe a fatal serious adverse event observed in a patient infused with autologous T-cell receptor (TCR) transduced T cells."( Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.
Bins, A; Blank, CU; Gomez-Eerland, R; Haanen, JB; Harper, JV; Hassan, NJ; Hulshoff, L; Jakobsen, BK; Jorritsma, A; Schumacher, TN; Tan, HL; van de Wiel, B; van den Berg, JH; van den Broek, D, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"Autologous DC were pulsed with MART-1(26-35) peptide and administered with a dose escalation of the CTLA4-blocking antibody tremelimumab."( Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Chmielowski, B; Cochran, AJ; Comin-Anduix, B; de la Rocha, P; Economou, JS; Glaspy, JA; Gomez-Navarro, J; Hui, L; Jalil, J; Marincola, FM; McCannel, TA; Ochoa, MT; Oseguera, DK; Ribas, A; Seja, E; Straatsma, BR; Villanueva, A; Wang, E, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Local bioavailability of MART-1(27-35) peptide for uptake and presentation by antigen-presenting cells was demonstrated for up to 6 days (>0."( Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix.
Brown, JM; Cole, DJ; Gattoni-Celli, S; McClay, EF; Metcalf, JS; Nabavi, N; Newton, DA; Vournakis, JN; Wilson, MC; Woolhiser, CB, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" To facilitate this study a Good Manufacturing Practice (GMP)-compliant plasmid manufacturing process was set up and a pharmaceutical dosage form was developed."( GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
Beijnen, JH; Haanen, JB; Nuijen, B; Quaak, SG; Schumacher, TN; Toebes, M; van den Berg, JH, 2008
)
0.35
" The pharmaceutical development of pDERMATT necessitated the availability of an assay for the quantification and purity determination of pDERMATT active pharmaceutical ingredient (API), the produced bulk drug and its pharmaceutical dosage form."( Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.
Beijnen, JH; Haanen, JB; Nuijen, B; Quaak, SG, 2009
)
0.35
" No significant influence of the route of immunization (subcutaneous versus intradermal) nor dosing regimen (weekly versus daily clusters) could be observed."( Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Bachmann, MF; Baumgaertner, P; Cerottini, JP; Conzett, KB; Devevre, E; Dummer, R; Geldhof, C; Guggisberg, D; Knuth, A; Kündig, T; Manolova, V; Romero, P; Schwarz, K; Senti, G; Speiser, DE; Sterry, W; Trefzer, U; Voelter, V; Walden, P; Willers, J; Zippelius, A, 2010
)
0.36
" Future studies are required to further characterize the effects of TXA on the histopathology and immunohistochemistry of melasma, to standardize dosing schedule, duration of treatment and long term outcome, of which there are no definitive guidelines at present."( Efficacy of oral tranexemic acid in refractory melasma: A clinico-immuno-histopathological study.
Bhattacharjee, R; Kumaran, MS; Nagaraju, D; Parsad, D; Saikia, UN; Vinay, K, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
HLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)IC50 (µMol)0.26240.26240.26240.2624AID50714
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.26240.00040.629810.0000AID50714
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.26240.00040.908610.0000AID50714
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.26240.00040.615610.0000AID50714
Gastrin/cholecystokinin type B receptorHomo sapiens (human)IC50 (µMol)0.26240.00010.36154.0000AID50714
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
T cell mediated cytotoxicityHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
T cell mediated cytotoxicity directed against tumor cell targetHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependentHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
peptide antigen assembly with MHC class I protein complexHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of T cell cytokine productionHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antibacterial humoral responseHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of type II interferon productionHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
CD8-positive, alpha-beta T cell activationHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
defense response to Gram-positive bacteriumHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
T cell receptor signaling pathwayHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell proliferationHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of memory T cell activationHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell activationHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
gastric acid secretionGastrin/cholecystokinin type B receptorHomo sapiens (human)
cell surface receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptorHomo sapiens (human)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
pH reductionGastrin/cholecystokinin type B receptorHomo sapiens (human)
digestive tract developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
gland developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
RNA bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
beta-2-microglobulin bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
T cell receptor bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
CD8 receptor bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
TAP complex bindingHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
cholecystokinin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
protein bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
peptide hormone bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
type B gastrin/cholecystokinin receptor bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
Golgi membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
endoplasmic reticulum membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
Golgi medial cisternaHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
endoplasmic reticulum exit siteHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
MHC class I peptide loading complexHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, A alpha chain Homo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
intracellular membrane-bounded organelleGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID50714MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Toward the quantitative prediction of T-cell epitopes: coMFA and coMSIA studies of peptides with affinity for the class I MHC molecule HLA-A*0201.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,179)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's106 (8.99)18.2507
2000's575 (48.77)29.6817
2010's424 (35.96)24.3611
2020's74 (6.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.28 (24.57)
Research Supply Index7.20 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials99 (7.98%)5.53%
Reviews62 (5.00%)6.00%
Case Studies233 (18.78%)4.05%
Observational2 (0.16%)0.25%
Other845 (68.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]